Valuation dashboard for Viridian Therapeutics, Inc. (VRDN) with P/E N/A, P/B 4.02, EV/EBITDA -7.82 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).
Analysis Summary
Viridian Therapeutics, Inc. reported revenue of $70.8M in the most recent fiscal year, growing at a 5-year CAGR of 132.2%.
Trailing-twelve-month margins: gross margin 99.6%, operating margin -5.7%, net margin -5.4%.
At $24.67 (closing price, October 30, 2026), VRDN has negative trailing earnings (P/E not meaningful) and an ROE of -61.35%. Market capitalisation stands at $2.8B.
Balance sheet quality for VRDN: current ratio of 12.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.02 |
| EV / EBITDA | -7.82 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-6.57 |
| vs Current Price | -126.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc. | $2.8B | 4.02 | -61.3% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $141.7B | 32.53 | 7.01 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.5B | 20.50 | 2.82 | 15.1% |
| MRNA | Moderna, Inc. | $88.5B | 12.99 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $56.1B | 42.54 | 6.74 | 16.9% |
| 0QNO.L | Lonza Group AG | CHF 43.8B | 5.43 | -1.3% |
Price
| Price | $24.67 (closing price, October 30, 2026) |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -61.35% |
| Return on Invested Capital | -39.18% |
| Return on Assets | -35.27% |
| Gross Margin | 99.55% |
| Operating Margin | -569.68% |
| Net Margin | -544.06% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of VRDN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks